Gan & Lee Pharmaceuticals Co. Ltd. Accelerates Innovation Amid Robust Revenue Growth

Gan & Lee Pharmaceuticals (603087.SH), headquartered in Beijing and listed on the Shanghai Stock Exchange, has reaffirmed its strategic focus on high‑risk, high‑reward innovation in the pharmaceutical sector. In a recent interview on Hushi Hui·Hard Science Hard Customer (第三季第1期), Executive Vice President and Chief Financial Officer Wang Qi outlined the company’s trajectory and the broader ecosystem that supports breakthrough drug development.

R&D as a Vehicle for Corporate Rebirth

Wang emphasized that each “breakthrough product” is essentially a corporate rebirth. The firm’s latest data reveal a 33 % allocation of revenue to research and development, a figure that has remained steady even as sales surged. This intensity in R&D underpins the company’s ambition to deliver “爆款” (blockbuster) drugs that can pivot market perception and unlock new revenue streams.

Revenue and Profit Milestones

  • 2025 Revenue: Exceeded RMB 40 billion, a clear leap from RMB 20 billion in 2023 and RMB 30 billion in 2024.
  • Net Profit: Surpassed RMB 11 billion, reflecting both sales expansion and operational efficiency.
  • Market Capitalization: Currently valued at approximately RMB 39.49 billion, with a price‑to‑earnings ratio of 39.71.
  • Stock Performance: The share price of RMB 66.34 on 10 September 2026 sits comfortably within its 52‑week range (high = 82.25, low = 51.51), indicating steady investor confidence.

These figures suggest that Gan & Lee’s revenue‑growth engine is resilient, even as it commits substantial resources to long‑term R&D.

Wang acknowledged the inherent uncertainty of cutting‑edge drug development. “The path to genuine innovation is fraught with setbacks,” he said. The company is therefore advocating for a capital‑market environment that tolerates failure as an inevitable part of progress. He called for the rapid extension of Kechengban (science‑and‑technology innovation board) policies to the main board, which would provide additional financial incentives and streamlined regulatory pathways for life‑science firms like Gan & Lee.

Forward‑Looking Outlook

  • Pipeline Momentum: With a robust pipeline of synthetic human insulins, insulin glargine injections, and associated medical equipment, the firm is well positioned to capitalize on rising global demand for advanced diabetes therapies.
  • Strategic Partnerships: Continued collaboration with academic institutions and international partners is expected to accelerate clinical translation and market entry.
  • Capital Efficiency: Maintaining a 33 % R&D spend while growing revenues suggests that the company is managing its capital allocation adeptly, balancing the need for innovation with profitability.

In summary, Gan & Lee Pharmaceuticals is navigating a dual mandate: sustaining a high‑growth revenue trajectory while investing aggressively in breakthrough drug development. Its recent performance, coupled with a strategic push for a more innovation‑friendly market framework, positions the company to lead the next wave of therapeutic breakthroughs in the Chinese and global pharmaceutical landscape.